Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$4.62 - $7.54 $106,532 - $173,864
-23,059 Reduced 37.77%
37,988 $203,000
Q1 2023

May 15, 2023

BUY
$4.82 - $7.24 $294,246 - $441,980
61,047 New
61,047 $437,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Delphia (Usa) Inc. Portfolio

Follow Delphia (Usa) Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Delphia (Usa) Inc., based on Form 13F filings with the SEC.

News

Stay updated on Delphia (Usa) Inc. with notifications on news.